Affiliation:
1. Department of Medicine and Therapeutics
2. Department of Medicine, University of Ghana Medical Centre, Accra, Ghana
Abstract
Helicobacter pylori (H. pylori)is endemic in Africa with a prevalence estimate of 79.1%. In addition, there is a significant community burden of dyspepsia in Africa, similar to other western countries. However, the majority of infected persons do not manifest the disease. In Africa, for instance, peptic ulcer disease is prevalent, whereas gastric cancer has reportedly low incidence. Therefore, it is important that testing is focused, targeting individuals most likely to benefit from treatment. In Africa, there are currently no guidelines forH. pyloritesting and treatment. Empirical treatment is common due to variable access to diagnostics and health care. To assess the spectrum ofH. pyloritesting in Africa, we performed a literature search in PubMed over the past 10 years, 2013 to 2023. Histology was the most widely used modality in 16 out of 18 countries. Capacity for culture was shown in 11 studies, importantly across regions of Africa.H. pyloriserology was demonstrated in 8 countries, although it has limited sensitivity in identifying active infection.H. pyloritest-and-treat strategy has been shown to be cost-effective. Particularly in a region with high antibiotic resistance, adopting this strategy ensures that only confirmed positive patients are treated. Furthermore, test-of-cure ought to be mandatory to guide future therapies. Health authorities can leverage polymerase chain reaction facilities, left behind by the coronavirus disease 2019 pandemic, to make molecular susceptibility testing available in the near future. A systematic approach to testing incorporating indication for endoscopy and medication use is recommended.
Publisher
Ovid Technologies (Wolters Kluwer Health)